Rockwell Medical (FRA:RWMA) Beta: 2.2720 (As of Jun. 25, 2026)


FRA:RWMA Rockwell Medical Inc FRA:RWMA
30 GF Score
Price €0.59
GF Value €0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical Beta?

Rockwell Medical FRA:RWMA +0.86% 30 Beta is 2.2720 as of Jun. 25, 2026. GuruFocus rates FRA:RWMA with a GF Score™ of 30/100 and a GF Value™ of €0.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Rockwell Medical's Beta is 2.2720.


Rockwell Medical  (FRA:RWMA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Rockwell Medical Beta Related Terms


Rockwell Medical Beta Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical Beta Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 0.88 0.49 1.08 1.32

Rockwell Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.49 1.46 1.32 1.81

FRA:RWMA vs MRMD, CPHI, HYEX: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rockwell Medical Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Beta distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's Beta falls into.


FRA:RWMA
30GF Score
Rockwell Medical Inc FRA:RWMA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rockwell Medical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.2720 mean?
Rockwell Medical (FRA:RWMA) has a Beta of 2.2720 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rockwell Medical and its competitors.
Is Rockwell Medical's Beta too high?
Rockwell Medical's current Beta is 2.2720. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Beta compare to MRMD and CPHI?
Rockwell Medical's Beta of 2.2720 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rockwell Medical and its competitors. Rockwell Medical's current Beta is 2.2720. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWMA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.75, compared to a current price of €0.59 — trading 22% below its estimated fair value. The current Beta is 2.2720. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Rockwell Medical (FRA:RWMA), the current Beta is 2.2720 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (FRA:RWMA) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued. The current stock price of €0.59 is trading 22% below its estimated GF Value™ of €0.75. GuruFocus considers Rockwell Medical to be Modestly Undervalued.

Key valuation signals for FRA:RWMA:

  • Beta: 2.2720
  • GF Value™: €0.75 vs. price of €0.59 (22% below fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rockwell Medical Business Description

Other Exchanges RMTI:USA
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score

Get the complete analysis for FRA:RWMA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.59
Price
€0.75
GF Value